Abivax SA
ABVXNasdaqGMPre-Market$133.26+37.11 (+38.60%)
Analyst avg. target $150.73(+13.11% upside)
Key Statistics
- Open
- 131
- Previous Close
- 96.15
- Day Range
- 128.21 – 137.11
- 52W Range
- 7.65 – 148.83
- Volume
- 8.51M
- Avg Volume (3M)
- 1.92M
- Market Cap
- 10.63B
- P/E (TTM)
- —
- Forward P/E
- -40.77
- EPS (TTM)
- -5.25
- Beta
- -0.2
- Dividend Yield
- —
- Profit Margin
- —
- Revenue (TTM)
- 4.92M
- Free Cash Flow
- -114.47M
- Debt/Equity
- 7.96
Analyst RatingsBuy
Low Target
$108.00
Avg Target
$150.73
High Target
$187.00
Strong Buy
4
Buy
6
Hold
1
Sell
0
Strong Sell
0
Based on 11 analysts
About
HealthcareBiotechnology80 employees
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
https://www.abivax.com